Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia

慢性淋巴细胞白血病 医学 CD38 人口 内科学 肿瘤科 癌症研究 白血病 免疫学 干细胞 生物 川地34 遗传学 环境卫生
作者
Elena Bibikova,Sara Parsa,Muskan Floren,Brian K. Law,Tracy Clevenger,Jean Cheung,Gary De Jesus,Kathleen A. Burke,Michael Gulrajani,Kyoko Yamaguchi,Phuong Do,Brian Dougherty,David Whitston,Graham Brock,Veerendra Munugalavadla,Melanie M. Frigault,Tanja Nicole Hartmann,John C. Byrd,Richard R. Furman,Jennifer R. Brown
出处
期刊:Hematological Oncology [Wiley]
卷期号:43 (1)
标识
DOI:10.1002/hon.70008
摘要

ABSTRACT Contemporary studies of Bruton tyrosine kinase inhibitor (BTKi) resistance focus on mutations in the B‐cell receptor (BCR) pathway, but alternative mechanisms of resistance remain undefined. Here, we sought to identify novel predictive markers of acquired resistance to acalabrutinib, a second‐generation BTKi, in patients with chronic lymphocytic leukemia (CLL). Clinical samples from 41 patients with relapsed/refractory or treatment‐naive CLL receiving acalabrutinib as part of a clinical trial (NCT02029443) were divided into two groups: those who continued to respond to treatment (NP, n = 23) and those who developed progressive disease on acalabrutinib therapy (PD, n = 18). Peripheral blood mononuclear cells (PBMCs) from the two groups of patients were profiled at baseline (BL) and at a second timepoint (T2) by RNA‐seq and flow cytometry. Our findings show a correlation between acquired resistance to acalabrutinib and upregulation of integrin alpha‐4 ( ITGA4 ; CD49d), the BCR surface receptor CD79B , and oncogenes such as MYC , LAG3 , and MCL1 in CLL cells. High surface expression of CD49d and CD79b prior to acalabrutinib therapy was associated with increased risk of disease progression on acalabrutinib in patients with CLL. When stratified by pretreatment CD49d surface expression, the CD49d hi group (defined as ≥ 30% CD49d+ cells at baseline) showed reduced acalabrutinib‐induced lymphocytosis and higher levels of tumor proliferation markers such as CD38 and Ki‐67 compared with the CD49d lo group (defined as < 30% CD49d+ cells at baseline). In summary, CD49d and CD79b are useful predictive markers for CLL progression on acalabrutinib. Trial Registration: ClinicalTrials.gov identifier: NCT02029443

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CK完成签到,获得积分10
刚刚
menghan发布了新的文献求助10
刚刚
耳喃完成签到,获得积分10
1秒前
Owen的应助被ee采纳,获得10
1秒前
完美世界的应助被nnn采纳,获得10
1秒前
高贵碧凡发布了新的文献求助10
1秒前
科研怪完成签到 ,获得积分10
1秒前
欣慰的冰旋完成签到 ,获得积分10
2秒前
隐形曼青的应助被你好采纳,获得10
2秒前
米朗心完成签到,获得积分10
2秒前
酷波er的应助被KK采纳,获得10
2秒前
2秒前
沙力VAN发布了新的文献求助10
2秒前
嘭嘭嘭发布了新的文献求助20
3秒前
33Rylee发布了新的文献求助10
3秒前
科研通AI6.2的应助被SZW采纳,获得10
3秒前
3秒前
百甲发布了新的文献求助10
3秒前
3秒前
科目三的应助被愤怒的之玉采纳,获得10
3秒前
打打的应助被yyw19930920采纳,获得10
3秒前
无花果的应助被还原糖采纳,获得10
3秒前
cole完成签到,获得积分10
3秒前
1111的应助被侯侯采纳,获得50
3秒前
专注的箴完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
SciGPT的应助被于海采纳,获得10
5秒前
hhh完成签到,获得积分10
5秒前
米朗心发布了新的文献求助10
5秒前
5秒前
6秒前
香蕉觅云的应助被陶陶采纳,获得10
6秒前
6秒前
SciGPT的应助被HJX采纳,获得10
6秒前
无极微光的应助被炙热百川采纳,获得20
6秒前
李定钊发布了新的文献求助10
6秒前
Lucas的应助被yourself采纳,获得10
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169168
求助须知:如何正确求助?哪些是违规求助? 9562182
关于积分的说明 21764903
捐赠科研通 7760775
什么是DOI,文献DOI怎么找? 3430228
关于科研通互助平台的介绍 2554080
邀请新用户注册赠送积分活动 2474932